A5077224052- Tuberculosis Research and Epidemiology
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- Mycobacterium research and diagnosis
- Global Health and Surgery
- Cancer therapeutics and mechanisms
- Pneumonia and Respiratory Infections
- Pharmacogenetics and Drug Metabolism
Partners In Health
2024-2025
Université de Montpellier
2024-2025
Assistance Publique – Hôpitaux de Paris
2024-2025
Institut de Recherche pour le Développement
2025
Sorbonne Université
2024-2025
Centre d'Immunologie et des Maladies Infectieuses
2024-2025
Inserm
2024-2025
University of Cape Town
2024
Brigham and Women's Hospital
2024
MedStar Health
2024
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis enhanced funding now permit randomized, controlled trials shortened-duration, all-oral treatments We conducted a phase 3, multinational, open-label, noninferiority trial compare standard therapy fluoroquinolone-susceptible, five 9-month oral regimens that included various combinations bedaquiline (B), delamanid (D),...
Background After a history of poor treatments for rifampin-resistant tuberculosis (RR-TB), recent advances have resulted in shorter, more effective treatments. However, they are not available to everyone and shortcomings, requiring additional treatment options. Methods endTB is an international, open-label, Phase 3 non-inferiority, randomized, controlled clinical trial compare five 9-month all-oral regimens including bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or...
<b>Objective:</b> To identify socio-demographic, clinical and laboratory risk factors associated with fibro-cavernous tuberculosis.<br /> <b>Material methods:</b> Clinical data of 184 patients pulmonary tuberculosis who were treated at the National Scientific Center for Phthisiopulmonology Ministry Healthcare Republic Kazakhstan analyzed. Specific antibodies to lipoglycan <i>M.tuberculosis</i> (<i>MBT</i>) evaluated in an...